Dry Eye Syndrome References

Last updated: 22 May 2025
  1. Fiscella RG. Understanding dry eye disease: a managed care perspective. Am J Manag Care. 2011 Dec;17(Suppl 16):S432-A439. https://secure.pharmacytimes.com/lessons/pdf/201112-02.pdf. Accessed 23 Jan 2012. PMID: 22435675
  2. Jackson WB. Management of dysfunctional tear syndrome: a Canadian consensus. Can J Ophthamol. 2009 Aug;44(4):385-394. http://www.eyesite.ca/CJO/4404/i09-015.pdf. Accessed 23 Jan 2012. PMID: 19606158
  3. International Dry Eye Committee. 2007 report of the International Dry Eye Workshop (DEWS). Ocul Surf. 2007 Apr;5(2):75-92. http://www.tearfilm.org/dewsreport/pdfs/TOS-0502-DEWS-noAds.pdf. Accessed 23 Jan 2012. PMID: 17508116
  4. Perry HD. Dry eye disease: pathophysiology, classification, and diagnosis. Am J Manag Care. 2008 Apr;14(3 Suppl):S79-S87. PMID: 18452371
  5. American Academy of Ophthalmology Cornea/External Disease Panel. Preferred practice pattern guidelines. Dry eye syndrome. San Francisco, CA: American Academy of Ophthalmology. http://one.aao.org/. 2013. Accessed 23 Jan 2012.
  6. Nam K, Kim HJ, Yoo A. Efficacy and safety of topical 3% diquafosol ophthalmic solution for the treatment of multifactorial dry eye disease: meta-analysis of randomized clinical trials. Ophthalmic Res. 2019 Jan;61(4):188-198. doi: 10.1159/000492896. Accessed 29 Jun 2021. PMID: 30654362
  7. Akpek EK, Amescua G, Farid M, et al; American Academy of Ophthalmology Preferred Practice Pattern Cornea and External Disease Panel. Dry eye syndrome Preferred Practice Pattern®. Ophthalmology. 2019 Jan;126(1):P286-P334. doi: 10.1016/j.ophtha.2018.10.023. PMID: 30366798
  8. Aragona P, Giannaccare G, Mencucci R, et al. Modern approach to the treatment of dry eye, a complex multifactorial disease: a P.I.C.A.S.S.O. board review. Br J Ophthalmol. 2021 Apr;105(4):446-453. doi: 10.1136/bjophthalmol-2019-315747. PMID: 32703782
  9. ClinicalKey. Clinical overview: dry eye. ClinicalKey. https://www.clinicalkey.com. 07 Nov 2020.
  10. Craig JP, Nichols KK, Akpek EK, et al. TFOS DEWS II Definition and classification report. Ocul Surf. 2017 Jul;15(3):276-283. doi: 10.1016/j.jtos.2017.05.008. PMID: 28736335
  11. Giannaccare G, Carnevali A, Senni C, et al. Umbilical cord blood and serum for the treatment of ocular diseases: a comprehensive review. Ophthalmol Ther. 2020 Jun;9(2):235-248. doi: 10.1007/s40123-020-00239-9. PMID: 32107737
  12. Jones L, Downie LE, Korb D, et al. TFOS DEWS II management and therapy report. Ocul Surf. 2017 Jul;15(3):575-628. doi: 10.1016/j.jtos.2017.05.006. PMID: 28736343
  13. Karakus S, Baer AN, Akpek EK. Clinical correlations of novel autoantibodies in patients with dry eye. J Immunol Res. 2019 Jan;2019:7935451. doi: 10.1155/2019/7935451. PMID: 30766890
  14. Liu Y, Kam WR, Ding J, et al. Can tetracycline antibiotics duplicate the ability of azithromycin to stimulate human meibomian gland epithelial cell differentiation. Cornea. 2015 Mar;34(3):342-346. doi: 10.1097/ICO.0000000000000351. PMID: 25611398
  15. Margo CE, Harman LE. Dry eye syndrome. In: Kellerman RD, Rakel D, eds. Conn's Current Therapy 2021. Philadelphia: Elsevier; 2021. 493-495. Accessed 22 Jun 2021:493-495.
  16. Nelson JD, Craig JP, Akpek EK, et al. TFOS DEWS II Introduction. Ocul Surf. 2017 Jul;15(3):269-275. doi: 10.1016/j.jtos.2017.05.005. PMID: 28736334
  17. U.S. Food and Drug Administration. Xiindra. US FDA. http://www.fda.gov. 2016.
  18. Wei Y, Troger A, Spahiu V, et al. The role of SKQ1 (Visomitin) in inflammation and wound healing of the ocular surface. Ophthalmol Ther. 2019 Mar;8(1):63-73. doi: 10.1007/s40123-018-0158-2. PMID: 30565203
  19. Akpek EK, Smith R. Current treatment strategies for age-related ocular conditions. Am J Manag Care. 2013 May;19(Suppl 5):S76-S84. http://www.ajmc.com. PMID: 23725499
  20. Barlett J, Karpecki P, Melton R, et al. Diagnostic & treatment algorithms for ocular surface disease states - updated edition. Dry eye - new paradigms in the understanding of dry eye. Review of Optometry. 2011 Oct:001-11. http://www.reviewofoptometry.com.
  21. Baudoiun C, Aragona P, Van Setten G, et al. Diagnosing the severity of dry eye: a clear and practical algorithm. Br J Ophthalmol. 2014 Sep;98(9):1168-1176. doi: 10.1136/bjophthalmol-2013-304619. PMID: 24627252
  22. Colligris B, Alzoki H, Pintor J. Recent development on dry eye disease treatment compounds. Saudi Journal of Ophthalmology. 2014;28:19-30. http://dx.doi.org/10.1016/j.sjopt.2013.12.003.
  23. Amescua G, Ahmad S, Cheung AY, et al. Dry eye syndrome preferred practice pattern. Ophthalmology. 2024 Apr;131(4):1-49. doi: 10.1016/j.ophtha.2023.12.041. PMID: 38349301
  24. Donthineni PR, Doctor MB, Shanbhag S, et al. Aqueous-deficient dry eye disease: preferred practice pattern guidelines on clinical approach, diagnosis, and management. Indian J Ophthalmol. 2023 Apr;71(4):1332-1347. doi: 10.4103/IJO.IJO_2808_22. PMID: PMID: 37026265
  25. Eom Y, Chung SH, Chung TY, et al. Efficacy and safety of 1% and 2% rebamipide clear solution in dry eye disease: a multicenter randomized trial. BMC Ophthalmol. 2023 Aug 3;23(1):343. doi: 10.1186/s12886-023-03004-1. PMID: 37537533
  26. Golden MI, Meyer JJ, Zeppieri M. Dry eye syndrome. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan. https://www.ncbi.nlm.nih.gov.
  27. Messmer EM, Ahmad S, Benitez Del Castillo JM, et al. . Management of inflammation in dry eye disease: recommendations from a European panel of experts. Eur J Ophthalmol. 2023 May;33(3):1294-1307. doi: 10.1177/11206721221141481. PMID: 36471573
  28. Rolando M, Merayo-Lloves J. Management strategies for evaporative dry eye disease and future perspective. Curr Eye Res. 2022 Jun;47(6):813-823. doi: 10.1080/02713683.2022.2039205. Accessed Accessed 15 Jul 2024. PMID: 35521685
  29. Shtein RM. Dry eye disease. UpToDate. https://www.uptodate.com. 31 May 2024.